Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Visit the company website

 

Bullboard - Investor Discussion Forum Voyageur Pharmaceuticals Ltd V.VM

Alternate Symbol(s):  VYYRF

Voyageur Pharmaceuticals Ltd. is a Canada-based company engaged in the development of barium and iodine Active Pharmaceutical Ingredients (API) and offers high-performance imaging contrast agents. The Company is focused on vertically integrating the barium and iodine contrast market, and aims at producing its own barium, iodine, and endo fullerenes. The Company’s products include SmoothX... see more

TSXV:VM - Post Discussion

Voyageur Pharmaceuticals Ltd > 2 weeks to lift off
View:
Post by whitenorth72 on Aug 19, 2022 9:00pm

2 weeks to lift off

Pick up what scraps are left. If all goes well we should be hitting some significant milestones soon.
Have a great weekend
Comment by WarrantOfficer on Aug 22, 2022 7:53am
I too have become critical of managements ability to lead this company. The lack of transparency affects credibility. Well over a year after the formation of the Scientific Advisory Board and hiring of Dash Consulting, zero progress has been shared. Formula Development for the 5 Health Canada Approvals has taken much to long and with zero explaination. Zero news after the PP as to what the funds ...more  
Comment by biggdogg on Aug 23, 2022 2:56pm
They laid everything out in May, closed financing, which was very small and not enough, due to dilution concerns, which is their only really dumb move, that was at end of june. Its only friggin August. Why would you expect anything so soon? I think once the FDA gets on track, then you will see timelines etc. The priority is building a mine, that is all that matters, Canadian sales is just a path ...more  
Comment by whitenorth72 on Aug 23, 2022 5:33pm
It's obvious one's motive to slander the company prior to the opening bell on a Monday what one's plan is for the week.. So I wouldn't waste time on explaining the company's plan because the position this person has taken is for their personal gain.
Comment by WarrantOfficer on Aug 24, 2022 7:17am
@biggdogg I hear you on the mine. I would like to know why the FDA is not on track. I have not read or been informed as to why the FDA timelines cannot be met. Further the June statement as to the allocation of the funds of the PP "The net proceeds of the Offering will be used to advance the product roll out of Health Canada licensed products for sales in Canada."  is IMO much to ...more  
Comment by Budd22 on Aug 24, 2022 10:45am
  They are working on regulatory pathways with FDA as contrast has been recently classified as a device not a drug. They have another meeting in September. Watch VM's last interview with investor intel on YouTube. Brent answers all your questions you keep posting there
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.


Connect with V.VM

follow v.vm on


Voyageur Pharmaceuticals Deck 2024..

The Watchlist

Voyageur Pharmaceuticals | The Watchlist
{{currentVideo.videoCaption}}
< Previous Video {{moreVideoText}} Next Video >

Investment Opportunity

COMPELLING
VALUE PROPOSITION

  • Only pharmaceutical company in the world that owns long-term supply of barium and iodine
  • Natural barium and iodine resources meet increasingly limited global supply and risk
  • Multi-billion-dollar global market for contrast media
  • Poised to obtain significant market share by offering high-quality, lower-cost products
  • Favorable regulatory pathway allows rapid commercialization
  • Highly experienced team has positioned the company for profitable commercial success

Contact Us

Brent Willis, CEO
Brent@Vpharma.ca

Address:
Suite 1600 Dome Tower, 333 7th Avenue S.W.
Calgary, Alberta
T2P 2Z1